SCHEMBL17015336

SCHEMBL17015336

c1ccc(-c2ccc3c4ccc(-c5cccc(-n6c7ccccc7c7ccc8ccn(-c9ccccc9)c8c76)c5)cc4c4ccccc4c3c2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.36
KDM4E B2RXH2 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
PDE10A Q9Y233 1/20 0.33
ALDH1A1 P00352 3/20 0.32
LMNA P02545 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
HTR6 P50406 2/20 0.32
WNK1 Q9H4A3 1/20 0.31
FAAH O00519 1/20 0.31
HSP90AA1 P07900 1/20 0.31
PKM P14618 1/20 0.31
HTT P42858 1/20 0.31
MGLL Q99685 1/20 0.31
MAOB P27338 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015333 0.99 KDM4E (0.36) ATMKDM4EL3MBTL1GAAMEN1
SCHEMBL17016209 0.95 L3MBTL1 (0.39) ATMKDM4EL3MBTL1GAAMEN1
SCHEMBL17015329 0.95 KDM4E (0.36) ATMKDM4EL3MBTL1GAAMEN1
SCHEMBL15683863 0.95 ATM (0.39) ATMKDM4EL3MBTL1GAAMEN1
SCHEMBL17015334 0.94 L3MBTL1 (0.40) ATMKDM4EL3MBTL1MEN1KMT2A
SCHEMBL17016207 0.94 L3MBTL1 (0.40) ATMKDM4EL3MBTL1MEN1KMT2A
SCHEMBL17016206 0.94 L3MBTL1 (0.40) ATMKDM4EL3MBTL1GAAMEN1
SCHEMBL15989366 0.93 L3MBTL1 (0.41) ATMKDM4EL3MBTL1MEN1KMT2A
SCHEMBL17015332 0.93 L3MBTL1 (0.41) ATMKDM4EL3MBTL1MEN1KMT2A
SCHEMBL17015388 0.92 KDM4E (0.38) ATMKDM4EL3MBTL1GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 ATM 3623/4885KDM4E 1286/4885L3MBTL1 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.